Genital herpes is a STD (Sexually transmitted disease) cause by two types of viruses, HSV-1 (Herpes simplex virus type 1) and HSV-2 (Herpes simplex virus type 2). Most people carrying virus doesn’t show symptom. It can be transmitted even when sore are not visible. Mothers having genital herpes can transmit it to her newborns during childbirth. The virus stays in human body for life as there is no entire cure. However, early diagnosis and proper medication can help to reduce symptoms of genital herpes, decrease outbreaks and help to minimize risk of transmission of virus to others.
According to case study by Future Market Insights, the global genital herpes treatment market is estimated to reach US$ 2,400 Mn by the end of 2027. The market is expected to register a CAGR of 4.4% during the forecast period. Genital herpes treatment market players are anticipated to attain potential market growth owing to increasing demand for treatment regarding sexually transmitted diseases in the near future. An analysts associated with the market researcher has answered some of the key queries regarding the expansion of the global genital herpes treatment market, and has revealed valuable insights as follows:
Based on your research over the recent past, what dynamic factors are responsible for the surging demand for genital herpes treatment across the globe?
Increasing incidences of occurrence of genital herpes among people is the most driving factor for genital herpes treatment market. Growing demand for such treatment among homosexual population is being observed to encourage adoption of genital herpes treatment. Symptoms for genital herpes are mostly identified among male same sex partners as compares to female same sex ones. Thereby, homosexual men are more prone to be at major risk to get affected by HSV-2 (Herpes simplex virus type 2). Thus, increasing diagnosis of HSV2 genital herpes and other virus like HIV (Human immunodeficiency virus) is expected to fuel up demand for genital herpes treatment during the forecast period.
Could you explain any specific development that took place in the recent past in genital herpes treatment?
Several companies are investing in research and development to increase clinical trials in order to integrate advancement in existing genital herpes treatments. This includes vaccination, surgeries and medication among others. Researcher at Geneva, Switzerland is investing in R&D to develop vaccination for genital herpes and increasing critical analysis in clinical trials of GEN-003. GEN-003 is identified as phase 3 ready investigational immunotherapy in treating infections due to genital herpes. This is a first advancement since 20 years in treatment of genital herpes. Such innovative developments are likely to strengthen genital herpes treatment market.
As per FMI’s demarcation on genital herpes treatment market, where do you think companies find potential opportunities in future?
Rising number of sexually transmitted diseases in the Middle East & Africa (MEA) is expected to offer valuable market share in genital herpes treatment market. Depending upon the route of administration, oral medication is highly likely to witness rise in demand among patients affected by genital herpes and thereby, increases demand for genital herpes treatment in the near future. Based on drug sales, a variety of drugs are available for genital herpes treatment which includes Valacyclovir, Acyclovir and Famciclovir. Among these, Acyclovir sales is expected to contribute towards revenue growth of genital herpes treatment market.
What do you perceive as the biggest deterrent for the adoption of genital herpes treatment?
Lack of awareness regarding sanitation and hygiene maintenance of genital areas leads towards sexually transmitted diseases. However, limitation to provision of treatment at impoverished part of the world due to high cost is expected to hinder market growth. In addition, lack of knowledge pertaining to genital herpes diseases and its aftereffect together with the limited access to medical facilities in hospital is highly likely to hamper revenue growth genital herpes treatment in the near future.
Who, do you think, are the key stakeholders in the global AMP market to account for potential opportunities for market expansion?
Several companies across the globe are investing heavily to diversify products portfolio in order to gain large customer base. Distribution channels such as retail pharmacies, e-commerce and online pharmacies among others. Market players are actively focusing on retail pharmacies in order to expand their business across the globe. Market players operating at North America such as Abbott Laboratories, Valeant Pharmaceuticals International Inc., and Pfizer Inc., are expected to account for remarkable opportunities in genital herpes treatment market during the forecast period. Other Teva Pharmaceutical Industries Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy’s Laboratories, ltd. and other APEJ market payers are anticipated to witness rise in coming years.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1390
